Viewing data from:

GANCICLOVIR SODIUM

ANDA

GANCICLOVIR SODIUM | A076222 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Ganciclovir Sodium (2023)

Total Spending

$61K

Total Claims

120

Beneficiaries

Avg Cost/Unit

$23.16

Spending Trend

$65K(2019)→$111K(2020)→$123K(2021)→$122K(2022)→$61K(2023)

YoY Change:+523.2%

5yr CAGR:+25.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF1 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

EXCELLA GMBH AND CO KGGANCICLOVIR SODIUM

DMF 169922003

HAINAN POLY PHARMACEUTICAL CO LTDInactiveGANCICLOVIR SODIUM

DMF 251222011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 500MG BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jul 16, 2003

No patent or exclusivity listings for this strength.